Treating LKB1 mutant tumors with compounds that increasing ROS or targeting KL tumors with glutamine inhibitors to reduce glutathione production inhibited tumor growth (Galan-Cobo et al., 2019). This evidence concerns the gene STK11 and neoplasm.